CN102293750A - Purpose of immunological nanoparticles of brucine in preparing anti-hepatoma target drugs - Google Patents
Purpose of immunological nanoparticles of brucine in preparing anti-hepatoma target drugs Download PDFInfo
- Publication number
- CN102293750A CN102293750A CN 201110210143 CN201110210143A CN102293750A CN 102293750 A CN102293750 A CN 102293750A CN 201110210143 CN201110210143 CN 201110210143 CN 201110210143 A CN201110210143 A CN 201110210143A CN 102293750 A CN102293750 A CN 102293750A
- Authority
- CN
- China
- Prior art keywords
- strychnine
- immune nano
- hepatoma
- nano microgranule
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a purpose of immunological nanoparticles of brucine in preparing anti-hepatoma target drugs. The immunological nanoparticles of brucine are immunological target nanoparticles which treat brucine as an active component and a carboxylated polyethylene glycol-polylactic acid segmented copolymer as a drug coating accessory, and are formed by externally linking with anti-human AFP monoclonal antibodies. The immunological nanoparticles of brucine provided by the invention, which have the characteristics of simple technology, high entrapment rate, stable drug release, and good balling, can be used for preparing antitumor target drugs which can be used for anti-hepatoma treatment. By intravenous injection, a nanometer carrier anti-human AFPMcAb-polyethylene glycol-polylactic acid segmented copolymer allows brucine aggregation in hepatoma cells to be increased, the drugs to be slowly and locally released, the effect time of the drugs to tumor cells to be prolonged, the local drug concentration to be improved, and the whole body toxicity of brucine to be reduced. So the immunological nanoparticles of brucine of the present invention have the advantages of accurate aggregation of target drugs in the cells of tumor tissues, stable drug release, good anticancer effect, safety and the like.
Description
Technical field
The present invention relates to the purposes that a kind of strychnine immune nano microgranule is used to prepare the medicine of tumour immunity targeted therapy, particularly, relate to the promptly anti-human a-fetoprotein monoclonal antibody of a kind of anti-people AFP McAb()-polyethylene glycol-lactic acid block copolymer strychnine immune nano microgranule is used to prepare the purposes of anti-liver cancer-specific target therapeutic agent.
Background technology
Strychnine (Brucine) is one of Semen Strychni main component, and its chemical constitution is as follows:
This strychnine is a kind of alkalescence alkaloid, poorly water-soluble, represent medicine as promoting blood circulation to remove obstruction in the collateral and " treating the poisonous disease with poisonous drugs ", the T lymphopoiesis there is facilitation, the function regulating action that the mouse lymphocyte function is had dose dependent, have tangible tumor-inhibiting action and very strong analgesic activity, Deng Xukun etc. estimate strychnine to the tumor inhibition effect of transplanted tumor model tumor-bearing mice and the influence of life span, found that strychnine all is not less than 30% at 1.61-6.46 mg to the tumour inhibiting rate of solid tumor Heps model mice and S180 model mice, strychnine can also improve the weight and the index thereof of the immune organ of mice, but it is to ascites tumor model (EAC, Heps) life span of tumor-bearing mice does not have obvious prolongation effect, thereby has confirmed that strychnine can suppress the growth of solid tumor models mouse interior tumor to a certain extent.Short application use does not have tangible toxicity to hemopoietic, immune system and the Liver and kidney of animal, can also stimulate and promote hemopoietic system and functions of immune system, recover the damage of the hepatic and renal function that mice causes because of the strain of inoculation hepatocarcinoma Heps tumor, strychnine may become new promising antitumor drug.
Prior art research: (1) preparation vauqueline liposome, contrast with strychnine solution, carrying out pharmacokinetic with White Rabbit finds, the administration of strychnine solution can not surveyed Brucine in the bleeding from anus in 2 hours, slow distribution half-life 7.5 minutes, and after strychnine is encapsulated in liposome, administration still kept certain CONCENTRATION DISTRIBUTION in the bleeding from anus in 12 hours, the elimination half-life has prolonged 6.6 than the former, but drug release is still too fast, and liver target is not strong, is difficult to reach in the part effective drug level; (2) strychnine and liposome thereof all show the obvious suppression effect to the growth of mouse bearing liver cancer (Heps) and mice transplanted solid tumor sarcoma S180 cell, but both do not have the prolongation effect to the life span of ascites tumor model (EAC and Heps) tumor-bearing mice; (3) strychnine polylactic acid nano particle (Bru-PLA-NPs) intravenous administration is used for the intravital pharmacokinetics observation of rabbit, found that single dose intravenous injection Bru-PLA-NPs (4 mg/ kg) back strychnine meets three-compartment model at the intravital medicine dynamics data of rabbit, meet two-compartment model behind the quiet notes strychnine of the single dose solution (4 mg/ kg), compare with strychnine solution, after the Bru-PLA-NPs administration, the elimination half-life of strychnine (t1/ 2 β) is improved 6.6 times; Bioavailability improves 8.7 times.Compare with strychnine solution, significant change has taken place in the intravital pharmacokinetics behavior of rabbit in strychnine behind the Bru-PLA-NPs intravenous administration, but strychnine is made nanoparticle prolong drug circulation and action time in animal body, improve bioavailability; (4) strychnine solution is used in the abdominal cavity, strychnine conventional liposome and strychnine hidden liposome treatment transplanted hepatoma H22 mice, strychnine dosage is 3.23mgkg-1, logotype 8d, found that strychnine solution with dosage, the strychnine conventional liposome, the tumour inhibiting rate of strychnine hidden liposome is respectively 28.64%, 57.96% and 71.36%, strychnine conventional liposome and hidden liposome all do not have immunosuppressive action to tumor-bearing mice, compare with conventional liposome, hidden liposome can further strengthen its antitumous effect as the carrier of strychnine.
Our recent research finds that strychnine and strychnine-polyethylene glycol-lactic acid block copolymer nano microgranule significantly suppress the SMMC-7721 human liver cancer cell and enter G2 from the S phase, the M phase, liver cancer apoptosis reducing, and strychnine nanoparticle inhibition tumor cell proliferation effect significantly is better than the strychnine monomer, strychnine can suppress the matrix adhesion of people's hepatocarcinoma SMMC-7721 cell, growth along with drug dose, the matrix adhesion inhibitory action is strengthened gradually, observation of cell motion migration rate was 17.46% when the strychnine consumption was 320 μ g/ml, the invasion and attack rate is 2.52%, compares migration rate with 40 μ g/ml and all there is significant difference in the invasion and attack rate.Show that strychnine can effectively suppress hepatoma carcinoma cell and adhere to, stop hepatoma carcinoma cell motion and invasion and attack, theoretical basis has been established in the further investigation that is used for the targeted therapy hepatocellular carcinoma for strychnine.
But strychnine is hypertoxic Chinese medicine, and its therapeutic dose and toxic dose are very approaching, and systemic administration dosage is big, and toxic and side effects is strong.How further improving the targeting and the tumor by local medicine of strychnine and assemble, continue the performance Graft Versus Tumor, reduce the whole body toxicity, is the key point that improves the anti-hepatocarcinoma effect of strychnine.
Summary of the invention
The purpose of this invention is to provide the promptly anti-human a-fetoprotein monoclonal antibody of a kind of anti-people AFP McAb()-polyethylene glycol-lactic acid block copolymer strychnine immune nano microgranule, can be used to prepare the liver neoplasm target therapeutic agent, make this medicine have the effect of the accurate targeting of tumor, Graft Versus Tumor and sustained and controlled release medicament.
For realizing above purpose, the invention provides the purposes that a kind of strychnine immune nano microgranule is used to prepare anti-hepatoma-targeting medicine, this strychnine immune nano microgranule is to be active component with the strychnine, with carboxylated polyethylene glycol-lactic acid block copolymer as pharmaceutical pack by adjuvant, link the immune targeted nano microgranule that anti-people AFP monoclonal antibody forms outward.
Above-mentioned strychnine immune nano microgranule is used to prepare the purposes of anti-hepatoma-targeting medicine, and wherein, it is 5 ~ 7% that described strychnine immune nano microgranule carries strychnine content, and envelop rate is 70 ~ 85%.
Above-mentioned strychnine immune nano microgranule is used to prepare the purposes of anti-hepatoma-targeting medicine, and wherein, described strychnine immune nano microgranule carries strychnine content 5.6 ± 0.2%, and envelop rate is 76.0 ± 2.3%.
Above-mentioned strychnine immune nano microgranule is used to prepare the purposes of anti-hepatoma-targeting medicine, wherein, the general formula of described carboxylated polyethylene glycol-lactic acid block copolymer is PLA-PEG-CH2-CH2-COOH, the scope of its molecular weight is 40-50kD, is that carboxylated Polyethylene Glycol and polylactic acid are that the ratio copolymerization of 1:1.5 ~ 3 forms with the part by weight.
Above-mentioned strychnine immune nano microgranule is used to prepare the purposes of anti-hepatoma-targeting medicine, wherein, described carboxylated polyethylene glycol-lactic acid block copolymer is that carboxylated Polyethylene Glycol and polylactic acid are that the ratio copolymerization of 1.5:2.5 forms with the part by weight.
Above-mentioned strychnine immune nano microgranule is used to prepare the purposes of anti-hepatoma-targeting medicine, and wherein, in the described strychnine immune nano microgranule, the weight ratio of strychnine and carboxylated polyethylene glycol-lactic acid block copolymer is 1:15 ~ 30.
Above-mentioned strychnine immune nano microgranule is used to prepare the purposes of anti-hepatoma-targeting medicine, and wherein, in the described strychnine immune nano microgranule, the weight ratio of strychnine and carboxylated polyethylene glycol-lactic acid block copolymer is 1:20.
Above-mentioned strychnine immune nano microgranule is used to prepare the purposes of anti-hepatoma-targeting medicine, and wherein, in the described strychnine immune nano microgranule, the concentration range of anti-people AFP monoclonal antibody is 10 ~ 20 μ g antibody/mg nanoparticles.
Above-mentioned strychnine immune nano microgranule is used to prepare the purposes of anti-hepatoma-targeting medicine, and wherein, in the described strychnine immune nano microgranule, the concentration of anti-people AFP monoclonal antibody is 15 μ g antibody/mg nanoparticles.
The present invention is active component with the strychnine, with the carboxylated Polyethylene Glycol of biodegradation material (carboxylation polyethylene glycol, CPEG) and polylactic acid (polylactic acid, PLA) as excipient substance, develop carboxylated polyethylene glycol-lactic acid block copolymer by chemical modification technique, adopt ultrasonic emulsification-chemical crosslink technique fabricating technology, preparation strychnine-carboxylated polyethylene glycol-lactic acid block copolymer nano microgranule (Brucine/CPEG/PLA Nanoparticles, BCPNS), to resist people AFP McAb and carboxylated polyethylene glycol-lactic acid block copolymer strychnine nanoparticle to link by chemical coupling method, the anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano microgranule of success development (Anti-hAFP McAb-Brucine/CPEG/PLA Nanoparticles, AHMBCPNS).Particle diameter 274.5 ± 64.3 nm, the Zeta current potential is-4.73 ± 4.73 mV, carrying drug ratio: 5.6 ± 0.2%, and envelop rate: 76 ± 2.3%, carrying strychnine concentration is 800 μ g/ml, and the concentration of anti-people AFP McAb on the strychnine nanoparticle is 15 μ g antibody/mg nanoparticles.Vitro drug release result: 24 hours cumulative release of strychnine surpass 80%, 48 hour and discharge fully.
The anti-people AFP of the present invention McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano microsome intracellular metabolite, tissue distribution and antitumor action:
Strychnine is at the half-life (t of strychnine group, strychnine nanoparticle group and strychnine immune nano microgranule group in the rat body
1/2) be respectively 6.98 ± 0.65 h, 16.88 ± 5.67 h and 15.69 ± 3.76 h.Strychnine nanoparticle group and strychnine immune nano microgranule group half-life obviously are longer than the strychnine group, and both in vivo metabolic process be close, promptly initially be the process of a tachymetabolism, eliminate slowly to the later stage, show tangible slow-releasing.And present a tachymetabolism process in the strychnine body.
All do not measure strychnine in each tissue in the strychnine group tumor bearing nude mice body behind the administration 3d, strychnine nanoparticle group strychnine concentration in the other hepatic tissue of spleen, lung, kidney, muscle, hepatocarcinoma and cancer is respectively 341.00 ng/ mg, 9.09 ng/mg, 7.90 ng/ mg, 14.41 ng/ mg, 24.00 ng/ mg and 246.50 ng/ mg, and remaining tissue is not measured; Strychnine immune nano microgranule group only in spleen, hepatocarcinoma and the other hepatic tissue of cancer strychnine concentration be respectively 341.50 ng/ mg, 57.13 ng/ mg and 135.93 ng/ mg.The drug level of strychnine immune nano microgranule group strychnine in liver cancer tissue is higher than strychnine nanoparticle group, and the strychnine drug level is starkly lower than strychnine nanoparticle group in the other hepatic tissue of cancer, difference have statistical significance (
F=445.85,
P＜0.05).
Tumour inhibiting rate is respectively 36.73%, 54.77%, 69.48%, 75.96% when strychnine immune nano microgranule group administration 7d, 14d, 21d and 30d, is significantly higher than other positive administration groups.The 5-Fu(5-fluorouracil) group, strychnine group, strychnine nanoparticle group and strychnine immune nano microgranule group tumor animal life cycle (d) are respectively 63.60 ± 16.26,50.10 ± 11.19%, 60.50 ± 12.54,81.50 ± 14.25, especially the longest with strychnine immune nano microgranule group life span, compare with other experimental grouies significant difference (
F=9.010,
P＜0.05); 5-Fu group, strychnine group, strychnine nanoparticle group and strychnine immune nano microgranule group increase in life span are respectively 25.20% ,-1.38%, 19.09% and 60.43%, and wherein strychnine immune nano microgranule group tumor animal life span obviously prolongs.
The present invention utilizes carboxylated Polyethylene Glycol and polylactic acid to form block copolymer, the copolymer end contains the water-soluble polymer Polyethylene Glycol to be inlayed, significantly improve long circulation time in the body, avoid in the strychnine immune nano microsome drug release rate too fast, be difficult to reach defectives such as effective antitumor drug level in the part.Utilize Polyethylene Glycol to expose carboxyl, successfully link by the chemical coupling technology, significantly improved the link efficiency of anti-people AFP McAb and carboxylated polyethylene glycol block copolymer strychnine nanoparticle with the amino of anti-people AFP McAb.
The anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano microgranule of the present invention's preparation, can be used for preparing the antineoplastic immune targeted drug, this medicine is used for the hepatocarcinoma treatment, after the peripheral vein administration, anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer nano carrier can increase strychnine to be assembled in hepatoma carcinoma cell, medicine is discharged in local slow, prolong drug is to the action time of tumor cell, improve local drug concentration, make its medicine carrying accumulate in tumor tissues more " accurately ", greatly bring into play the strychnine antitumor action, reduce the toxic action of strychnine to greatest extent; Have advantages such as accurate target tumor histiocyte medicine is assembled, drug release is stable, and anticancer effect is good, and is safe.
Description of drawings
Fig. 1 is a carboxylated polyethylene glycol-lactic acid block copolymer (PLA-PEG-CH2-CH2-COOH)
1H-NMR measures collection of illustrative plates.
Fig. 2 a is anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano
The microgranule transmission electron microscope picture, transmission electron microscope * 10,000.
Fig. 2 b is anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano
The microgranule sem photograph, scanning electron microscope * 50,000.
Fig. 3 is anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano diameter of particle scattergram.
Fig. 4 is anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano microgranule vitro drug release.
Fig. 5 is anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano microgranule targeting mensuration.
Fig. 6 is that anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano microgranule is to the hepatoma cell growth inhibitory action.
Fig. 7 is anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano microgranule pharmacokinetics.
Fig. 8 is that anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano microgranule distributes at the tumor bearing nude mice in-vivo tissue.
Fig. 9 is anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano microgranule antitumor action.
Figure 10 is that anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano microgranule is to tumor animal influence life cycle.
The specific embodiment
Describe the specific embodiment of the present invention in detail below in conjunction with accompanying drawing.
The preparation method of anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano microgranule
Composition of raw materials is as follows:
Wherein, polymeric material (PLA-PEG-CH2-CH2-COOH) is that carboxylated Polyethylene Glycol and polylactic acid are the carboxylated polyethylene glycol-lactic acid block copolymer of ratio (preferred 1.5:2.5) the copolymerization formation of 1:1.5 ~ 3 with the part by weight; Its general formula is PLA-PEG-CH2-CH2-COOH, and the scope of its molecular weight is 40-50kD, and its structure fragment reaches
1H-NMR measures collection of illustrative plates as shown in Figure 1.
Above-mentioned oil phase and water are mixed, disperse with the high shear dispersing emulsification machine, 12000rpm rotating speed down cut 5min gets dispersion liquid, again this dispersion liquid is continued emulsifying under 300w power ultrasonic condition, and ultrasonic 5 times, each 30s gets colostric fluid.Colostric fluid is poured in the diluent of recipe quantity, the limit edged stirs, and mixing speed 700rpm continues to stir 6-8h and carries out fluid drying under normal temperature condition, fling to CH
2Cl
2, with the centrifugal 10min under the 5000rpm rotating speed of the emulsion behind the fluid drying, remove possible aggregation (comprising carboxylated polyethylene glycol-lactic acid block copolymer, polyvinyl alcohol), collect supernatant and promptly get the strychnine nanoemulsions.With strychnine nanoemulsions (the Millipore Amicon100 in the ultra-filtration centrifuge tube that packs into, 000), at centrifugal force 3, centrifugal 30min under the 000g condition, concentrate and remove free strychnine, concentrate the back and use the purified water concentrated solution for washing, ultrafiltration is once centrifugal again, obtain strychnine nanoparticle concentrated solution
60The Co irradiation sterilization, 4 ℃ of refrigerators are preserved standby.
30ml strychnine medicine-carried nano particles concentrated solution is divided into 10 parts, be every part of 3ml, in every part of medicine-carried nano particles concentrated solution, add 5mg EDAC(carbodiimide hydrochloride), shaking table vibration 15min(200rpm/min), after adding AFP antibody (1mg/ml) then, 4 ℃ of shaking table vibration 3h(200rpm/min), centrifugal again 5 minutes 10000 rpm, 0.01M PBS(pH 7.4) wash particle 3 times.By the centrifugation of centrifugal force, nanoparticle is connected the back, and coagulation is at the pipe end under action of centrifugal force with antibody, and the antibody that does not connect can not avale under the rotating speed of 10000rpm and is suspended in the upper strata.Obtain strychnine immune nano microgranule concentrated solution through the ultrafiltration centrifugalize, in 4 ℃ of refrigerators, preserve standby.
Strychnine immune nano detection of particulates is the result show, particle size is even, the profile rounding, particle diameter 274.5 ± 64.3 nm, as Fig. 2 a, Fig. 2 b and shown in Figure 3, the Zeta current potential is-4.73 ± 4.73 mV, carrying drug ratio: 5.6 ± 0.2%, envelop rate: 76 ± 2.3%, carrying strychnine concentration is 800 μ g/ml, the concentration of anti-people AFP McAb on the strychnine nanoparticle is 15 μ g antibody/mg nanoparticles.Vitro drug release result: 24 hours cumulative release of strychnine surpass 80%, 48 hour and discharge fully.Anticancer experiment in vitro: strychnine immune nano microgranule has obvious inhibitory action to hepatoma carcinoma cell SMMC-7721 growth, and is with the increase inhibitory action of drug level and increases progressively trend, has concentration dependent.Compare with the strychnine nanoparticle with strychnine, strychnine immune nano microgranule is approaching to inhibitory action and the 5-FU of hepatoma carcinoma cell SMMC-7721, IC
50(5-FU organizes IC to differ minimum
50Be 16.7 μ g/ml; Strychnine immune nano microgranule group IC
50Be 28.2 μ g/ml).
Embodiment 2
The outer drug release test of anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano microsome
Precision pipettes strychnine immune nano microgranule concentrated solution 2.0ml, placing molecular cut off is 3, in the 000 daltonian bag filter, tighten at two ends, 3 parts of operation repetitives, put in the PBS medium of 50ml pH7.4, in 37 ℃, carry out release in vitro under the 100rpm speed conditions, discharge beginning back the 0.5th, 1,2,4,8,12,16,18,24,36, the 48h 4ml that takes a sample, fluid infusion 4ml, sample measure the UV absorption value under the 263nm wavelength, calculate Bru(strychnine in the release medium) concentration and cumulative release percentage rate.
Compound concentration is a 0.427mg/mlBru-PBS solution in addition, precision pipettes this solution 2.0ml, placing molecular cut off is 3, in the 000 daltonian bag filter, tighten at two ends, 3 parts of operation repetitives, put in the PBS medium of 50mlpH7.4, in 37 ℃, carry out release in vitro under the 120rpm speed conditions, discharge beginning back the 10th, 20,30,60,120,210, the 300min 4ml that takes a sample respectively, fluid infusion 4ml, sample is measured the UV absorption value under the 263nm wavelength, calculate the concentration and the cumulative release percentage rate of strychnine in the release medium, is used to investigate the retardation that bag filter discharges strychnine.
Release in vitro result shows: 24 hours cumulative release of strychnine surpass 80%, 48 hour and discharge fully, as shown in Figure 4.
Embodiment 3
Anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano microgranule targeting mensuration
To resist people AFP McAb strychnine immune nano particle and hepatoma carcinoma cell SMMC-7721 to hatch 4h, use 0.01M PBS washed cell 3 times; With two anti-addings of FITC labelling, continue to hatch 2h, after PBS washing 3 times; Under Laser Scanning Confocal Microscope, observe and replenish immunofluorescence method.200 times of Laser Scanning Confocal Microscopes show that down strychnine immune nano microgranule comparatively is evenly distributed near the hepatoma carcinoma cell film, present approximate " referring to guard against " shape, show good targeting location, as shown in Figure 5 (photo under the Laser Scanning Confocal Microscope * 200 times).
Embodiment 4
Anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano microgranule is to the liver cancer cell growth inhibitory action
Need be divided into RPMI-1640 group, 5-FU group, strychnine group, strychnine nanoparticle group, PLA-PEG-CH2-CH2-COOH block copolymer nano microgranule group, anti-people AFP McAb group, the blank immune nano microgranule group of anti-people AFP McAb and strychnine immune nano microgranule group according to experiment.Strychnine group, strychnine nanoparticle group and strychnine immune nano particulate constituent are not chosen the different strychnine concentration of 10,20,40,80,160,240 μ g/ml, the molar dose of contained blank nanoparticle under blank nanoparticle matched group consumption and the corresponding equal drug level of nanoparticle that contains strychnine, 5-FU chooses 10,20,40 μ g/ml respectively.External act on SMMC-7721 hepatoma carcinoma cell 72h respectively after, adopt mtt assay to measure each group to hepatoma carcinoma cell SMMC-7721 growth inhibition ratio.The result shows: the drug effect of (1) negative control group (RPMI-1640 group, PLA-PEG-CH2-CH2-COOH block copolymer nano microgranule group, anti-people AFP McAb group, anti-people AFP McAb-PEG-PLA block copolymer group) variable concentrations 72 hours does not all have obvious inhibitory action to people's hepatocarcinoma SMMC-7721 cell, increase along with drug level, each organizes medicine does not all have obvious inhibitory action to the growth of people's hepatocarcinoma SMMC-7721 cell, equal not statistically significant (P〉0.05).(2) medicine of each group (strychnine group, strychnine nanoparticle group, strychnine immune nano microgranule group) variable concentrations of 5-FU group and experiment all has obvious inhibitory action to people's hepatocarcinoma SMMC-7721 cell, the identical time of drug effect, increase along with drug level, each organizes medicine all has obvious inhibitory action to the growth of people's hepatocarcinoma SMMC-7721 cell, between group in twos comparing difference statistical significance (P＜0.05) is arranged, as shown in Figure 6.
Anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano microgranule pharmacokinetics
Choose 6 of healthy male Wistar rats, dosage with 3.23mg/kg injects strychnine, strychnine nanoparticle and strychnine immune nano microgranule through the tail vein, inject back 5min, 10min, 15min, 30min, 45min, 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h respectively the tail vein get blood 0.5ml and place the anticoagulant test tube, 1500rpm * 5min, it is standby in 4 ℃ of frozen pipes to draw blood plasma.Adopt the 3200Q-Trap tandem mass spectrometer to measure a time point blood plasma strychnine concentration.Strychnine t1/2 is 6.98 ± 0.65 h, strychnine nanoparticle t
1/2Be 16.88 ± 5.67 h, strychnine immune nano microgranule t
1/2Be 15.69 ± 3.76 h, the result shows, relative strychnine, and strychnine immune nano microgranule significant prolongation strychnine circulation time in vivo (sees Table 1, Fig. 7).
Table 1: pharmacokinetics (n=6) behind the strychnine immune nano microgranule intravenously administrable
Embodiment 6
Anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano microgranule distributes in lotus hepatocarcinoma nude mouse inner tissue
Set up nude mice orthotopic transplantation liver cancer model, 2 weeks after the modeling, by nude mice tail intravenously administrable, dosage with 3.23mg/kg injects strychnine through the tail vein, strychnine nanoparticle and strychnine immune nano microgranule, 72hr after the administration, leave and take the tumor bearing nude mice heart, liver, spleen, lung, kidney, brain, stomach, muscle, fat, cancerous tissue, volume ratio 1:2 adding distil water by weight, tissue homogenate, get homogenate 100 μ l, add mark (loratadine 100ng/ml) in the 10 μ l, add 400 μ l acetonitriles, vortex vibration, the centrifugal 3min of 15000rpm, get supernatant 100 μ l and be transferred to sample introduction in the sample introduction pipe, adopt the 3200Q-Trap tandem mass spectrometer to measure strychnine nanoparticle tissue distribution in vivo.The result shows 72hr after the administration, strychnine is not all measured at above-mentioned each tissue concentration, and the concentration of strychnine nanoparticle group in liver, spleen and tumor all is higher than lung, kidney, muscle, remaining tissue is not all measured, and the drug level in the tumor tissues is 23.96ng/ml, liver 246.5 ng/ml, spleen 341 ng/ml, lung 9.09 ng/ml, kidney 7.89 ng/ml, muscle 14.4 ng/ml.72hr liver tumor targeting index is 71.42 after the administration; Kidney, lung, muscle etc. organize Chinese medicine concentration obviously to reduce, medicine metabolism time lengthening in vivo, and tumor target tissue concentration is higher.Strychnine immune nano microgranule group only in spleen, tumor and the other hepatic tissue of cancer strychnine concentration be respectively 341.50 ng/ mg, 57.13 ng/ mg and 135.93 ng/ mg.The drug level of strychnine in liver cancer tissue is higher than strychnine nanoparticle group, and the strychnine drug level is starkly lower than strychnine nanoparticle group in the other hepatic tissue of cancer, difference have statistical significance (
F=445.85,
P＜0.05), as shown in Figure 8.
Embodiment 7
The effect of anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano microgranule treatment nude mice hepatocarcinoma
Set up nude mice orthotopic transplantation liver cancer model, be divided into normal saline group (NS), blank nanoparticle group (being PLA-PEG-CH2-CH2-COOH block copolymer nano microgranule group), anti-people AFP McAb group, the blank immune nano microgranule of anti-people AFP McAb group, 5-FU group, strychnine group, strychnine nanoparticle group and strychnine immune nano microgranule group at random.Respectively through the tail vein inject normal saline, the 5-FU(consumption is 20mg/kg), strychnine (consumption is 3.23mg/kg), blank nanoparticle consumption is the corresponding molar dose that contains contained blank nanoparticle under the equal drug level of strychnine nanoparticle.Put to death nude mice behind each group treatment 30d, respectively organize gross tumor volume, neoplasm necrosis degree; Adopt the TUNEL labelling method to detect apoptosis rate, Use immunohistochemistrySP SP detects the expression of Ki-67.The result shows: compare with 5-FU group (tumor control rate is 58.87 ± 1.67%), strychnine group (tumor control rate is 47.08 ± 2.69%), strychnine nanoparticle group (tumor control rate is 51.38 ± 3.18%) function of tumor inhibition is similar to 5-FU, and difference has statistical significance (P＜0.05); Tumour inhibiting rate is respectively 36.73%, 54.77%, 69.48%, 75.96% when strychnine immune nano microgranule group administration 7d, 14d, 21d and 30d, is significantly higher than 5-Fu group, strychnine group, strychnine nanoparticle group, as shown in Figure 9.
Anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano microgranule is to tumor animal influence life cycle
Set up nude mice orthotopic transplantation liver cancer model, be divided into normal saline group, blank nanoparticle group, anti-people AFP McAb group, the blank immune nano microgranule of anti-people AFP McAb group, 5-FU group, strychnine group, strychnine nanoparticle group and strychnine immune nano microgranule group at random.Respectively through the tail vein inject normal saline, the 5-FU(consumption is 20mg/kg), strychnine (consumption is 3.23mg/kg), blank nanoparticle consumption is the corresponding molar dose that contains contained blank nanoparticle under the equal drug level of strychnine nanoparticle.Therapeutic outcome shows, 5-Fu group, strychnine group, strychnine nanoparticle group and strychnine immune nano microgranule group tumor animal life cycle (d) are respectively 63.60 ± 16.26,50.10 ± 11.19,60.50 ± 12.54,81.50 ± 14.25, especially the longest with strychnine immune nano microgranule group life span, compare with other experimental grouies significant difference (
F=9.010,
P＜0.05), shows that strychnine immune nano microgranule has good targeting, significantly improve the strychnine Graft Versus Tumor, prolong tumor animal life cycle, as shown in figure 10.
The present invention utilizes anionic polymerisation and chemical modification technique to prepare carboxylated Polyethylene Glycol and polylactic-acid block copolymer material, develop carboxylated polyethylene glycol-lactic acid block copolymer strychnine nanoparticle by ultrasonic emulsification and chemical crosslinking technology, prepare anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer strychnine immune nano microgranule by chemical coupling method, can be used for preparing the antineoplastic immune targeted drug, this medicine is used for the hepatocarcinoma treatment, after the peripheral vein administration, anti-people AFP McAb-polyethylene glycol-lactic acid block copolymer nano carrier can increase strychnine to be assembled in hepatoma carcinoma cell, medicine is discharged in local slow, prolong drug is to the action time of tumor cell, improve local drug concentration, reduce the strychnine general toxicity; Have advantages such as accurate target tumor histiocyte medicine is assembled, drug release is stable, and anticancer effect is good, and is safe.
Although content of the present invention has been done detailed introduction by above preferred embodiment, will be appreciated that above-mentioned description should not be considered to limitation of the present invention.After those skilled in the art have read foregoing, for multiple modification of the present invention with to substitute all will be conspicuous.Therefore, protection scope of the present invention should be limited to the appended claims.
Claims (9)
1. a strychnine immune nano microgranule is used to prepare the purposes of anti-hepatoma-targeting medicine, this strychnine immune nano microgranule is to be active component with the strychnine, with carboxylated polyethylene glycol-lactic acid block copolymer as pharmaceutical pack by adjuvant, link the immune targeted nano microgranule that anti-people AFP monoclonal antibody forms outward.
2. strychnine immune nano microgranule as claimed in claim 1 is used to prepare the purposes of anti-hepatoma-targeting medicine, it is characterized in that, it is 5 ~ 7% that described strychnine immune nano microgranule carries strychnine content, and envelop rate is 70 ~ 85%.
3. strychnine immune nano microgranule as claimed in claim 2 is used to prepare the purposes of anti-hepatoma-targeting medicine, it is characterized in that, described strychnine immune nano microgranule carries strychnine content 5.6 ± 0.2%, and envelop rate is 76.0 ± 2.3%.
4. be used to prepare the purposes of anti-hepatoma-targeting medicine as any described strychnine immune nano microgranule of claim 1 ~ 3, it is characterized in that, the general formula of described carboxylated polyethylene glycol-lactic acid block copolymer is PLA-PEG-CH2-CH2-COOH, the scope of its molecular weight is 40-50kD, is that carboxylated Polyethylene Glycol and polylactic acid are that the ratio copolymerization of 1:1.5 ~ 3 forms with the part by weight.
5. strychnine immune nano microgranule as claimed in claim 4 is used to prepare the purposes of anti-hepatoma-targeting medicine, it is characterized in that described carboxylated polyethylene glycol-lactic acid block copolymer is that carboxylated Polyethylene Glycol and polylactic acid are that the ratio copolymerization of 1.5:2.5 forms with the part by weight.
6. be used to prepare the purposes of anti-hepatoma-targeting medicine as any described strychnine immune nano microgranule of claim 1 ~ 3, it is characterized in that, in the described strychnine immune nano microgranule, the weight ratio of strychnine and carboxylated polyethylene glycol-lactic acid block copolymer is 1:15 ~ 30.
7. strychnine immune nano microgranule as claimed in claim 6 is used to prepare the purposes of anti-hepatoma-targeting medicine, it is characterized in that, in the described strychnine immune nano microgranule, the weight ratio of strychnine and carboxylated polyethylene glycol-lactic acid block copolymer is 1:20.
8. be used to prepare the purposes of anti-hepatoma-targeting medicine as claim 1 or 2 or 3 or 5 or 7 described strychnine immune nano microgranules, it is characterized in that, in the described strychnine immune nano microgranule, the concentration range of anti-people AFP monoclonal antibody is 10 ~ 20 μ g antibody/mg nanoparticles.
9. strychnine immune nano microgranule as claimed in claim 8 is used to prepare the purposes of anti-hepatoma-targeting medicine, it is characterized in that, in the described strychnine immune nano microgranule, the concentration of anti-people AFP monoclonal antibody is 15 μ g antibody/mg nanoparticles.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102101431A CN102293750B (en) | 2011-06-30 | 2011-07-26 | Purpose of immunological nanoparticles of brucine in preparing anti-hepatoma target drugs |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110181615.5 | 2011-06-30 | ||
| CN201110181615 | 2011-06-30 | ||
| CN2011102101431A CN102293750B (en) | 2011-06-30 | 2011-07-26 | Purpose of immunological nanoparticles of brucine in preparing anti-hepatoma target drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102293750A true CN102293750A (en) | 2011-12-28 |
| CN102293750B CN102293750B (en) | 2012-08-22 |
Family
ID=45048878
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110210126 Expired - Fee Related CN102266291B (en) | 2011-06-30 | 2011-07-26 | Preparation method of strychnine immune nanoparticles |
| CN2011102101431A Expired - Fee Related CN102293750B (en) | 2011-06-30 | 2011-07-26 | Purpose of immunological nanoparticles of brucine in preparing anti-hepatoma target drugs |
| CN2011102101361A Expired - Fee Related CN102293749B (en) | 2011-06-30 | 2011-07-26 | Brucine immune nanoparticles |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110210126 Expired - Fee Related CN102266291B (en) | 2011-06-30 | 2011-07-26 | Preparation method of strychnine immune nanoparticles |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102101361A Expired - Fee Related CN102293749B (en) | 2011-06-30 | 2011-07-26 | Brucine immune nanoparticles |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN102266291B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102871966B (en) * | 2012-10-19 | 2013-11-20 | 东南大学 | Nano drug carrier particles for improving bioavailability of rapamycin and preparation method thereof |
| CN110252218B (en) * | 2019-07-18 | 2021-07-27 | 广东省医疗器械研究所 | Protein-modified polymer microsphere composite material, and preparation method and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1365711A (en) * | 2001-01-15 | 2002-08-28 | 杨孟君 | Nano vomiting nut medicine and its preparing process |
| CN1698611A (en) * | 2005-06-07 | 2005-11-23 | 华东理工大学 | Nanometer vauqueline liposome and preparation method thereof |
| EP1746090A1 (en) * | 2005-07-15 | 2007-01-24 | Laboratorios del Dr. Esteve S.A. | Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood |
| WO2007009706A2 (en) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood |
| WO2008106646A2 (en) * | 2007-03-01 | 2008-09-04 | Introgen Therapeutics, Inc | Methods and formulations for topical gene therapy |
| CN101426369A (en) * | 2006-02-27 | 2009-05-06 | 西北大学 | Composition in the form of a microemulsion containing free fatty acids and/or free fatty acid derivatives |
| CN101524448A (en) * | 2008-03-04 | 2009-09-09 | 华东理工大学 | Analgesic and anti-inflammatory Chinese medicinal composition as well as preparation method and application of preparation thereof |
| CN101612357A (en) * | 2009-02-13 | 2009-12-30 | 西安正大制药有限公司 | A kind of Chinese medicine composition for the treatment of tumor and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1603513B1 (en) * | 2003-03-04 | 2020-12-30 | Lyotropic Therapeutics, Inc. | Dantrolene compositions |
| CN1698612A (en) * | 2005-06-07 | 2005-11-23 | 华东理工大学 | Nanometer vauqueline liposome transdermal spray agent, its preparation method and application thereof |
| CN101548953B (en) * | 2008-04-03 | 2011-10-05 | 上海医药工业研究院 | Medicine granule, preparation method thereof, and preparation containing same |
| CN101700277A (en) * | 2009-11-13 | 2010-05-05 | 江苏科技大学 | Sustained-release pill of total alkaloids from strychnos and method for preparing same |
-
2011
- 2011-07-26 CN CN 201110210126 patent/CN102266291B/en not_active Expired - Fee Related
- 2011-07-26 CN CN2011102101431A patent/CN102293750B/en not_active Expired - Fee Related
- 2011-07-26 CN CN2011102101361A patent/CN102293749B/en not_active Expired - Fee Related
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1365711A (en) * | 2001-01-15 | 2002-08-28 | 杨孟君 | Nano vomiting nut medicine and its preparing process |
| CN1698611A (en) * | 2005-06-07 | 2005-11-23 | 华东理工大学 | Nanometer vauqueline liposome and preparation method thereof |
| EP1746090A1 (en) * | 2005-07-15 | 2007-01-24 | Laboratorios del Dr. Esteve S.A. | Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood |
| WO2007009706A2 (en) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood |
| CN101426369A (en) * | 2006-02-27 | 2009-05-06 | 西北大学 | Composition in the form of a microemulsion containing free fatty acids and/or free fatty acid derivatives |
| WO2008106646A2 (en) * | 2007-03-01 | 2008-09-04 | Introgen Therapeutics, Inc | Methods and formulations for topical gene therapy |
| CN101524448A (en) * | 2008-03-04 | 2009-09-09 | 华东理工大学 | Analgesic and anti-inflammatory Chinese medicinal composition as well as preparation method and application of preparation thereof |
| CN101612357A (en) * | 2009-02-13 | 2009-12-30 | 西安正大制药有限公司 | A kind of Chinese medicine composition for the treatment of tumor and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 《中国中药杂志》 20090915 赵继会等 马钱子碱聚乳酸载药纳米粒的制备和体外评价 , 第18期 * |
| 《中国新药杂志》 20060623 邓旭坤等 马钱子碱及其脂质体对移植性肝癌Heps小鼠的抗肿瘤作用和毒性的比较 , 第12期 * |
| 《中草药》 20081112 徐睿等 马钱子碱对人肝癌细胞HepG2细胞膜电位和通透性的影响 , 第11期 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102293749A (en) | 2011-12-28 |
| CN102293750B (en) | 2012-08-22 |
| CN102266291B (en) | 2013-01-16 |
| CN102266291A (en) | 2011-12-07 |
| CN102293749B (en) | 2012-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Designer exosomes enabling tumor targeted efficient chemo/gene/photothermal therapy | |
| Zhao et al. | Nanotechnology for cancer therapy based on chemotherapy | |
| Xu et al. | Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma | |
| Zou et al. | Drug resistance reversal in ovarian cancer cells of paclitaxel and borneol combination therapy mediated by PEG-PAMAM nanoparticles | |
| Poon et al. | Controlling in vivo stability and biodistribution in electrostatically assembled nanoparticles for systemic delivery | |
| Hao et al. | Hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery | |
| Du et al. | Ultrasound-triggered drug release and enhanced anticancer effect of doxorubicin-loaded poly (D, L-lactide-co-glycolide)-methoxy-poly (ethylene glycol) nanodroplets | |
| Wang et al. | Stealth polydopamine-based nanoparticles with red blood cell membrane for the chemo-photothermal therapy of cancer | |
| CN101926775B (en) | Preparation and application methods of difunctional naonparticle preparation entrapping vincristine sulphate | |
| Wang et al. | Lung cancer chemotherapy using nanoparticles: enhanced target ability of redox-responsive and pH-sensitive cisplatin prodrug and paclitaxel | |
| Xin et al. | PLGA nanoparticles introduction into mitoxantrone-loaded ultrasound-responsive liposomes: In vitro and in vivo investigations | |
| Li et al. | Multifunctional liposome for photoacoustic/ultrasound imaging-guided chemo/photothermal retinoblastoma therapy | |
| Tsai et al. | Photothermal, targeting, theranostic near-infrared nanoagent with SN38 against colorectal cancer for chemothermal therapy | |
| CN111479593B (en) | Quinic acid-modified nanoparticles and uses thereof | |
| Wu et al. | Homologous cancer cell membrane-camouflaged nanoparticles target drug delivery and enhance the chemotherapy efficacy of hepatocellular carcinoma | |
| Wang et al. | A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (−) prostate cancer specific therapy | |
| Chen et al. | Response of pH-sensitive doxorubicin nanoparticles on complex tumor microenvironments by tailoring multiple physicochemical properties | |
| Hu et al. | Rational design of an amphiphilic chlorambucil prodrug realizing self-assembled micelles for efficient anticancer therapy | |
| Fan et al. | Lignin-assisted construction of sub-10 nm supramolecular self-assembly for photothermal immunotherapy and potentiating anti-PD-1 therapy against primary and distant breast tumors | |
| CN102293750B (en) | Purpose of immunological nanoparticles of brucine in preparing anti-hepatoma target drugs | |
| Siddiqui et al. | CD44 mediated colon cancer targeting mutlifaceted lignin nanoparticles: Synthesis, in vitro characterization and in vivo efficacy studies | |
| CN106265513B (en) | A kind of effect of nano-paclitaxel and preparation method thereof | |
| Huang et al. | Development of curcumin-loaded galactosylated chitosan-coated nanoparticles for targeted delivery of hepatocellular carcinoma | |
| Tao et al. | Fe3O4 Nanoparticles Embedded in Pectin–Doxorubicin Composites as pH-Responsive Nanoplatforms for Tumor Diagnosis and Therapy by T 1-Weighted Magnetic Imaging | |
| Liu et al. | Nanoscale functional biomaterials for cancer theranostics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120822 Termination date: 20160726 |